Category: AstraZeneca shares plunge 16 percent as lung cancer study fails

AstraZeneca shares plunge 16 percent as lung cancer study fails

  1. AstraZeneca shares plunge 16 percent as lung cancer study fails  CNBC
  2. AstraZeneca Takeover Chatter Bubbles Up Again After Massive Drug Trial Disappointment  TheStreet.com
  3. AstraZeneca shares plunge 16 percent on lung cancer failure  Nasdaq
  4. AstraZeneca’s Missing Takeover Defense  Bloomberg
  5. AstraZeneca plummets 16pc to offset FTSE 100 earnings-inspired gains on Super Thursday  Telegraph.co.uk
  6. Full coverage

from Business – Google News http://www.cnbc.com/2017/07/27/astrazeneca-shares-plunge-16-percent-as-lung-cancer-study-fails.html

Advertisements